You are here

Press Release Archive

- Pfizer Extends 10 Million Yuan to Earthquake Victims and Relief Efforts in China

(BUSINESS WIRE)--Today Pfizer China announced it is providing up to RMB 10 million (approximately $1.4 million U.S.D) in medicines and financial assistance to relief organizations operating in the region worst affected by the massive earthquake. “We were devastated to hear about the rising death tolls and escalating number of injuries in Sichuan Province,” said Ahmet Esen,

- Esperion Therapeutics Completes $22.75 M Series A Financing


- U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent

(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a communication notifying the company that it will confirm the patentability of the claims of Pfizer's ‘893 basic patent for Lipitor. The Patent Office had conducted a re-examination of the ‘893 patent in response to a request by a law firm that represented the generic company Ranbaxy Laboratories Limited. The patent, which expires

- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer, Jeffrey B. Kindler, at the 33rd Annual Deutsche Bank Healthcare Conference on Monday, May 5th at 12:40pm Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site homepage at and click on the “Deutsche Bank Healthcare

- Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology

(BUSINESS WIRE)--Pfizer has entered into a collaboration agreement with four major research universities – University of California, Santa Barbara (UCSB); Caltech; the Massachusetts Institute of Technology; and University of Massachusetts – and Entelos, a physiological modeling company, to re-examine the regulatory mechanisms of human energy metabolism. Pfizer is funding the three-year and $14 million Insulin

- Pfizer Declares a 32-Cent Second Quarter, 2008, Dividend

The board of directors of Pfizer Inc today declared a 32-cent second–quarter, 2008, dividend on the company’s common stock, payable June 3, 2008, to shareholders of record at the close of business on May 9, 2008. The second-quarter 2008 cash dividend will be the 278th consecutive quarterly dividend paid by Pfizer, and 2008 marks the 41st consecutive year of annual dividend increases for Pfizer

- Pfizer on Track to Deliver Greater Shareholder Value, CEO Kindler Tells Shareholders

(BUSINESS WIRE)--Today at Pfizer’s annual shareholder meeting, Chairman and Chief Executive Officer Jeffrey B. Kindler detailed his plan to build on the Company’s foundation to drive greater shareholder return. “Operationally, in 2007, we took a series of significant actions to better position Pfizer to meet our challenges and to seize the many opportunities before us in the growing global marketplace

- Pfizer Animal Health Enters into Agreement to Acquire Animal Health Products from Schering-Plough

(BUSINESS WIRE)--Pfizer Animal Health today announced that it has entered into an agreement to acquire multiple product franchises from Schering-Plough Corporation covering all major animal health species including cattle, swine, equine, and companion animal. Specifically, Pfizer Animal Health will acquire from Schering-Plough a number of animal health products for sale in the European Economic Area covering the following categories

- Pfizer Japan to Launch Champix(R) the First Prescription Oral Smoking Cessation Aid in Japan

(BUSINESS WIRE)--Pfizer Inc announced today that on May 8, 2008, it will launch Champix® Tablet 0.5mg/1mg (varenicline tartrate), a novel smoking cessation aid for smokers with nicotine dependence in Japan, which has one of the highest rates of smoking among developed nations. Champix was developed as the first non-nicotine drug designed for smoking cessation in the United States and will be the first oral smoking cessation aid

- Pfizer Invites Public to Listen to Webcast of April 24 Annual Shareholders Meeting

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Central Daylight Time) on Thursday, April 24. To access the webcast, visit our Web site at and click on the “Annual Meeting of Shareholders” webcast link in the Investor Presentations tab on our homepage. Information on accessing and pre-registering for the webcast will be

- High-Dose Lipitor Reduced the Risk of Heart Attack and Stroke in Patients with Chronic Kidney Disease

Pfizer Inc announced today that Lipitor® (atorvastatin calcium) 80 mg reduced the risk of heart attack and stroke by 32 percent in patients who have heart disease and chronic kidney disease compared with patients taking the 10 mg dose of Lipitor. This analysis, designed and completed following the closure of the five-year Treating to New Targets (TNT) study, was published in the “Journal of the American

- Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT

Pfizer Japan Inc announced that on April 16, the company received an approval for the manufacturing and marketing authorization of the anti-tumor drug/kinase inhibitor “SUTENT® Capsule 12.5 mg” (sunitinib malate) indicated for Gastrointestinal Stromal Tumor (GIST) after failure of imatinib treatment due to resistance and for Renal Cell Carcinoma (RCC) not indicated for curative resection and Metastatic Renal

- Pfizer Opens New Development Centre

(BUSINESS WIRE)--A new development centre for veterinary vaccines which will accelerate the development of new animal health products has been opened by Pfizer as part of its annual $300 million (US dollar) commitment to research and development. The new centre is located on the Louvain-la-Neuve scientific plant near Brussels. "This is an historic occasion for Pfizer Animal Health,” said Juan Ramon

- Federal Court in Canada Upholds Pfizer's Norvasc Patent; Decision Prevents Launch of Generic Amlodipine Besylate Product by Pharmascience until 2010

(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued an order prohibiting regulatory approval of Pharmascience’s proposed product in Canada until Pfizer’s amlodipine besylate patent - Canadian Patent No. 1,321,393 - expires in August 2010. Pharmascience may appeal the decision to the Federal Court of Appeal

- Pfizer Reports First-Quarter 2008 Results; Reaffirms Full-Year 2008 Financial Guidance

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):         ($ in millions, except per share amounts)         First Quarter   2008

- Results from Largest Statin Study of Patients with Alzheimer's Disease Show Lipitor(R) Has No Significant Impact on Disease

(BUSINESS WIRE)--In a study in patients with mild-to-moderate Alzheimer’s disease (AD), the addition of Lipitor (atorvastatin calcium tablets) 80 mg to Aricept® (donepezil HCl) 10 mg showed no significant differences in cognition or global function (key measures of Alzheimer’s progression) compared to placebo plus Aricept 10 mg. Furthermore, no statistically significant differences were seen on various cognitive, behavioral

- Lyrica Reduced Pain of Fibromyalgia in Patients Regardless of Symptoms of Anxiety or Depression

Pfizer’s Lyrica reduced pain of fibromyalgia in patients regardless of whether they experienced symptoms of anxiety or depression at the beginning of the study, according to a pooled analysis presented today at the American Academy of Neurology annual meeting. The analysis, which looked at data pooled from previous clinical trials, also showed that patients’ self-reported improvements were more closely associated

- Pfizer Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc.

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the subsequent offering period of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes, expired as of 5:00 p.m., New York

- Pfizer Statement on Exubera Labeling Update in the United States

(BUSINESS WIRE)--Pfizer Inc said today that it updated the US product labeling for EXUBERA® (insulin human [rDNA original]) Inhalation Powder to include a warning with safety information about lung cancer cases observed in patients who used Exubera. This update is based on an ongoing review of the data from the Exubera clinical trial program and post-marketing experience by Pfizer and the Food and Drug Administration (FDA)


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.